Individuals with IBD, especially CD, have an increased risk for myocardial infarction, ischemic heart disease, cerebrovascular accident, and major adverse cardiovascular events.

Background In inflammatory bowel disease (IBD), a new biological therapy has recently been approved. Vedolizumab is a humanised IgG1 monoclonal antibody to α4β7 integrin that modulates gut lymphocyte ...

The ACG has published new health maintenance recommendations for patients with IBD, which include appropriate vaccinations, ...

Background The development of IBD is known to involve early immunological alterations, but our understanding of the changes ...